UK Markets open in 7 hrs 37 mins

Genmab A/S (GMAB.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2,636.00-86.00 (-3.16%)
At close: 04:59PM CEST
Full screen
Previous close2,722.00
Open2,720.00
Bid2,636.00 x N/A
Ask2,647.00 x N/A
Day's range2,636.00 - 2,734.00
52-week range1,863.00 - 3,124.00
Volume126,179
Avg. volume112,324
Market cap172.445B
Beta (5Y monthly)0.60
PE ratio (TTM)60.59
EPS (TTM)43.50
Earnings date21 Feb 2022 - 25 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est2,687.91
  • Motley Fool

    Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript

    Genmab is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our privacy policy.

  • Globe Newswire

    Genmab Announces Financial Results for the First Half of 2022

    August 10, 2022 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2022 Highlights Genmab and AbbVie Inc. (AbbVie) announced topline results for epcoritamab from the Phase 1/2 trial in patients with relapsed/refractory large B-cell lymphoma (LBCL)Genmab announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for epcoritamab for the treatment of patients with relapsed/refractory LBCL, in the second half of 2

  • Globe Newswire

    Genmab Improves Its 2022 Financial Guidance

    Company Announcement Genmab improves its 2022 financial guidance COPENHAGEN, Denmark; August 8, 2022 – Genmab A/S (Nasdaq: GMAB) announced today that it is improving its 2022 financial guidance published on May 11, 2022. The improved guidance is driven primarily by increased royalty revenue due to higher net sales of DARZALEX and the positive net foreign exchange impact of the strong U.S. Dollar. Genmab expects its 2022 revenue to be in the range of DKK 12,000 – 13,000 million, an increase to th